Additional Biomarkers Give Hope to Breast Cancer Research
In the middle of breast cancer awareness month, independent analysis firm Datamonitor Healthcare has highlighted a number of potential drug targets that could be used to treat the most frequent cancer among women.
As multiple signalling pathways are often disrupted in cancer cells, a combination of therapies, which target different biomarkers, may hold the key to effective breast cancer therapies.
Vascular endothelial growth factor (VEGF) remains the focus of many early-stage pipeline drugs, but other targets such as phosphoinositide-3-kinases (PI3Ks) and cyclin-dependent kinases (CDKs) are increasingly becoming the focus of research into new drugs.
Activating PIK3 CA mutations in the PI3K pathway are common to approximately 30% of breast cancer tumours and has been linked to the resistance of chemotherapy. The number of therapeutics targeting the PI3K pathway has increased during the past few years, with preclinical and clinical studies showing a degree of efficacy. For example, Novartis’s buparlisib is a pan-PI3K inhibitor currently in Phase III development.
Pfizer and Onyx’s palbociclib is an interesting and highly selective CDK inhibitor which targets CDK5 and CDK6 resulting in G1 arrest and, therefore, halts cell and tumour growth.
Dr Colin White, lead oncology analyst at Datamonitor Healthcare said: “Past difficulties in introducing new biological drugs into the clinical setting have identified the need for more selective R&D models and appropriate clinical trial designs. This involves the identification of biomarkers to predict a patient’s response to therapy.
“Predictive biomarkers can provide invaluable information for the identification of patients who are likely to respond to a specific drug. These drug targets will allow the development of safe and effective treatment plans for individual patients which could have a huge impact on the treatment of breast cancer.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance